HTL Biotechnology launches HTL8
A new production unit dedicated to pharmaceutical-grade Polynucleotides (DNA) at our Javené site.
On 12 November, HTL Biotechnology inaugurated HTL8, a new production unit at its Javené site in France dedicated to the manufacture of pharmaceutical-grade Polynucleotides.
Representing a €15 million investment, HTL8 is a new milestone in the Group’s industrial strategy. It is designed to meet growing global demand for biopolymers and to support new applications in regenerative medicine, ophthalmology and dermatology.
“[…] HTL8 is a perfect illustration of this: it anchors in France an industrial excellence capable of shining on a global scale, supporting our customers closely in their markets and contributing, through increasingly innovative pharmaceutical-grade biopolymers, to the healthcare solutions of tomorrow,” says François Fournier, CEO of HTL Biotechnology.
Discover how HTL8 strengthens our 45 years of expertise in polynucleotides, and what it means for our customers worldwide, in our press release.
HTL Biotechnology hosted a scientific summit in Chengdu, China, dedicated to PDRN/PN, bringing together more than 130 experts and professionals to discuss the latest scientific advances, regulatory developments and emerging applications.
Driven by the collective commitment of our teams, this report confirms the maturity of an internationally recognized approach, which was recognized this year with the EcoVadis Platinum medal, placing HTL Biotechnology among the top 1% of the world’s most committed companies.
On June 4th, as part of the 3rd edition of the National Biopharmaceutical Bioproduction Day (#JNBB2026) organized by France BioLead, HTL Biotechnology was pleased to open the doors of its Javené facility to students and teachers who came to learn about careers in bioproduction.